Company Overview
Snapshot
Founded in January 2016 by Yoel Ezra, EFA Technologies operates with 11–50 employees. The company has raised $9.49 million across 9 funding rounds from 7 investors. In April 2024, EFA Technologies entered the Brazilian market following Anvisa approval for its portable RevDx device.
Business overview
EFA Technologies develops the RevDx, an affordable handheld blood test diagnostic tool designed for infectious disease diagnosis. This mobile end-point solution performs automatic microscopy tests, including whole blood sampling and automated blood count diagnosis. The RevDx is user-friendly, requiring only a finger-prick blood sample without the need for laboratory conditions, enabling real-time informed decisions. The platform serves as a programmable portable lab for integrated community case management, focusing on safe, precise, and affordable testing, treating, and tracking of infectious diseases, starting with parasitology and blood cell count. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Healthcare.
Strategic signal
EFA Technologies' entry into the Brazilian market in April 2024, following Anvisa approval for its portable RevDx device, signals significant market expansion and regulatory validation. This move indicates the company's capability to navigate international regulatory landscapes and tap into new, large healthcare markets, suggesting strong growth potential and broader adoption of its diagnostic technology.
Log in to access full profile ›Company Intelligence Q&A
- What is EFA Technologies' primary product?
- EFA Technologies' primary product is the RevDx, an affordable handheld blood test diagnostic tool designed for the diagnosis of infectious diseases.
- When was EFA Technologies founded and by whom?
- EFA Technologies was founded in January 2016 by Yoel Ezra.
- What significant market expansion did EFA Technologies achieve in April 2024?
- In April 2024, EFA Technologies entered the Brazilian market after receiving Anvisa approval for its portable RevDx device.
- Which investors participated in the April 2024 funding round?
- In April 2024, EFA Technologies received funding from Maccabi Healthcare Services and Israel Innovation Authority.
- What was a notable grant received by EFA Technologies?
- In March 2021, EFA Technologies received a grant from the Israel Innovation Authority.